VERVE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.16 USD | -0.96% |
|
-7.23% | -55.81% |
| Apr. 03 | Stifel Cuts Price Target on Verve Therapeutics to $40 From $56, Maintains Buy Rating | MT |
| Apr. 02 | Sector Update: Health Care Stocks Slide Late Afternoon | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,776 | 1,192 | 1,121 | 517 | - | - |
| Enterprise Value (EV) 1 | 1,416 | 637.2 | 497.2 | 77.06 | 312.8 | 277.2 |
| P/E ratio | -8.23 x | -6.65 x | -4.47 x | -2.1 x | -2.02 x | -1.91 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 614 x | 95.3 x | 39.7 x | 51.6 x | 30.4 x |
| EV / Revenue | - | 328 x | 42.3 x | 5.92 x | 31.2 x | 16.3 x |
| EV / EBITDA | -16.6 x | -3.91 x | -2.28 x | -0.29 x | -1.03 x | -0.8 x |
| EV / FCF | -17.2 x | -4.7 x | -3.28 x | -0.35 x | -1.37 x | -1.2 x |
| FCF Yield | -5.81% | -21.3% | -30.5% | -285% | -73.1% | -83.5% |
| Price to Book | 2.77 x | 1.9 x | 1.49 x | 1.13 x | 1.47 x | 1.66 x |
| Nbr of stocks (in thousands) | 48,171 | 61,604 | 80,424 | 83,923 | - | - |
| Reference price 2 | 36.87 | 19.35 | 13.94 | 6.160 | 6.160 | 6.160 |
| Announcement Date | 3/14/22 | 3/2/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 1.941 | 11.76 | 13.01 | 10.02 | 16.98 |
| EBITDA 1 | - | -85.53 | -162.9 | -217.7 | -263.5 | -302.5 | -345.2 |
| EBIT 1 | - | -87.07 | -165.7 | -223.1 | -234.5 | -264.3 | -294.5 |
| Operating Margin | - | - | -8,536.17% | -1,897.64% | -1,802.24% | -2,636.74% | -1,733.93% |
| Earnings before Tax (EBT) 1 | - | -120.3 | -157.3 | -199.8 | -226.2 | -254.3 | -284.4 |
| Net income 1 | -45.7 | -120.3 | -157.4 | -200.1 | -226.2 | -254.3 | -283.6 |
| Net margin | - | - | -8,108.55% | -1,701.55% | -1,738.64% | -2,537.23% | -1,669.94% |
| EPS 2 | - | -4.480 | -2.910 | -3.120 | -2.929 | -3.057 | -3.232 |
| Free Cash Flow 1 | - | -82.24 | -135.6 | -151.7 | -219.4 | -228.6 | -231.5 |
| FCF margin | - | - | -6,984.23% | -1,290.47% | -1,686.78% | -2,281.18% | -1,363.1% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 5/28/21 | 3/14/22 | 3/2/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 0.929 | 1.012 | 1.404 | 2.093 | 3.117 | 5.143 | 2.25 | 2.639 | 2.256 | 5.978 | 3 |
| EBITDA 1 | - | -32.07 | - | - | -43.14 | -46.78 | - | - | -50.86 | - | -62 | -65 | -69 | -73 | - |
| EBIT 1 | -23.5 | -32.54 | -31.92 | -42.19 | -43.86 | -47.71 | -58.26 | -58.58 | -52.33 | -53.95 | -57.71 | -59.13 | -61.44 | -60.36 | -64 |
| Operating Margin | - | - | - | - | -4,721.21% | -4,714.33% | -4,149.5% | -2,799% | -1,678.99% | -1,048.98% | -2,564.68% | -2,240.65% | -2,723.82% | -1,009.74% | -2,133.33% |
| Earnings before Tax (EBT) 1 | -22.75 | -31.34 | -30.17 | -40.95 | -45.19 | -41.03 | -51.98 | -53.81 | -45.69 | -48.32 | -55.11 | -56.57 | -59.07 | -57.65 | -64 |
| Net income 1 | -22.75 | -31.34 | -30.17 | -40.95 | -45.19 | -41.08 | -51.98 | -53.98 | -45.76 | -48.35 | -55.11 | -56.57 | -59.07 | -57.65 | -64 |
| Net margin | - | - | - | - | -4,864.37% | -4,059.68% | -3,701.92% | -2,579.22% | -1,468.01% | -940.17% | -2,449.44% | -2,143.86% | -2,618.98% | -964.4% | -2,133.33% |
| EPS 2 | -0.4700 | -0.6500 | -0.6200 | -0.8400 | -0.7900 | -0.6700 | -0.8400 | -0.8700 | -0.7200 | -0.6900 | -0.7133 | -0.7289 | -0.7600 | -0.7267 | -0.8700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/14/22 | 5/10/22 | 8/9/22 | 11/7/22 | 3/2/23 | 5/15/23 | 8/10/23 | 11/7/23 | 2/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 360 | 555 | 624 | 440 | 204 | 240 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -82.2 | -136 | -152 | -219 | -229 | -232 |
| ROE (net income / shareholders' equity) | - | -82% | -34.7% | -34.8% | -50.5% | -69.5% | -79.4% |
| ROA (Net income/ Total Assets) | - | -52% | -29.6% | -27.9% | -42.2% | -61.7% | -72.8% |
| Assets 1 | - | 231.3 | 531.7 | 716.1 | 536 | 412.1 | 389.6 |
| Book Value Per Share 2 | - | 13.30 | 10.20 | 9.340 | 5.440 | 4.180 | 3.700 |
| Cash Flow per Share | - | - | -2.260 | - | - | - | - |
| Capex 1 | - | 4.36 | 13.2 | 9.28 | 10 | 9.22 | 8.85 |
| Capex / Sales | - | - | 681.71% | 78.95% | 77.02% | 92% | 52.11% |
| Announcement Date | 5/28/21 | 3/14/22 | 3/2/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
6.16
USD
Average target price
31.22
USD
Spread / Average Target
+406.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -55.81% | 517M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- VERV Stock
- Financials Verve Therapeutics, Inc.
